CONTRAST MEDIA CONTRAST AGENT MARKET ANALYSIS

Market News

Rising Product launch and inorganic growth strategies such as acquisition and collaboration by the market players is expected to bolster the contrast media contrast agent market

Key players are focused on product approvals and launches, in order to gain major market share which is expected to drive the contrast media contrast agent market growth. For instance, in September 2019, Bayer HealthCare launched Medrad Stellant Flex CT injection system in order to offer user-driven system, individualized patient protocols and personalized imaging. Similarly, in July 2019, Bracco Diagnostics Inc., a subsidiary of Bracco Imaging S.p.A., launched an interactive and customizable media kit for enhancing the user experience and increasing physician referrals. The media kit includes customizable press release, patient brochure, and letter and referrers brochure.

In July 2019, Bayer HealthCare, received the U.S. Food and Drug Administration approval for its Gadavist (gadobutrol) injection to be used as the first contrast agent for cardiac magnetic resonance (MR) imaging in the patients suspected to suffer from the coronary artery disease.

In March, 2017, GE Healthcare launched Clariscan, a gadolinium based contrast agent designed to support effective visualization of abnormalities in the spine, brain and associated tissues.

Additionally increasing adoption of merger and acquisition strategies by the market players is also considered as a major factor driving market growth. For instance, in December 2014, nanoPET Pharma GmbH and Boehringer Ingelheim Corporation announced partnership. Under the partnership nanoPET led the development of contrast agents for studies in both basic and pre-clinical research.